Posmeal MD

Uses
Posmeal MD (Voglibose) is indicated to treat type 2 diabetes; to treat type 1 diabetes; and to prevent type 2 diabetes.

Posmeal MD (Voglibose) helps reduce blood glucose level by blocking the intestinal alpha-glucosidase, which is one of the hydrolase enzymes and which are involved in breaking down such components of carbohydrates as saccharides, including disaccharides, oligosaccharides, and polysaccharides. Once the activity of alpha-glucosidase is reduced, the complex carbohydrates breakdown and glucose absorption are slowed down as well - it leads to the reduction of postprandial blood glucose level, also known as postprandial hyperglycemia. At the same time, the medication does not affect beta-glucosidase activity in any way.

Posmeal MD (Voglibose) is absorbed slowly and poorly and is eliminated quickly via the intestine. No Voglibose metabolites have been discovered in human body and urine.

Dosage and Administration
Posmeal MD (Voglibose) is manufactured 0.2 and 0.3mg tablets. The tablets should be taken immediately before every meal with a full glass of water.

Normally, the initial dose, prescribed to adult patients does not exceed 0.2mg, three times daily. However, it may be increased to 0.3mg, three times daily, at the discretion of your physician. The initial dose, prescribed to elderly patients normally does not exceed 0.1mg, three times daily. However, it may be increased to 0.2 or 0.3mg, at the discretion of your physician.

Side effects
If any of the following side effects occur while taking Posmeal MD (Voglibose), check with your doctor immediately:

• Bloating
• Bowel obstruction
• Diarrhea
• Elevated liver transaminase level
• Flatulence
• Fulminant hepatitis
• Hypoglycaemia
• Jaundice
• Severely impaired liver function

Precautions
Administration of the drug during pregnancy and breastfeeding period.
Posmeal MD (Voglibose) can be prescribed during pregnancy or in case of suspected pregnancy only if the expected therapeutic effect exceeds any potential risks. There is no available safety data on using Posmeal MD (Voglibose) in pregnant patients. It is advisable to avoid using Posmeal MD (Voglibose) in breastfeeding patients. However, if it is necessary to use Posmeal MD (Voglibose), breastfeeding has to be suspended.

Reaction rate when driving motor vehicles or operating other machinery.
Posmeal MD (Voglibose) is likely to cause adverse event that may affect the capability to drive motor vehicles or operate machinery.

Children.
There is no available safety data on using Posmeal MD (Voglibose) in children, therefore it shouldn't be prescribed to this group of patients.